LEF1 or TCF1 alpha participates in the Wnt signaling pathway, activates transcription of target genes in the presence of CTNNB1 and EP300. It may play a role in hair cell differentiation and follicle morphogenesis. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by LEF1 and CTNNB1. It regulates T-cell receptor alpha enhancer function. PIAG antagonizes both Wnt-dependent and Wnt-independent activation by LEF1. Isoform 3 lacks the CTNNB1 interaction domain and may be an antagonist for Wnt signaling. Isoform 5 transcriptionally activates the fibronectin promoter, binds to and represses transcription from the E-cadherin promoter in a CTNNB1-independent manner, and is involved in reducing cellular aggregation and increasing cell migration of pancreatic cancer cells. Isoform 1 transcriptionally activates MYC and CCND1 expression and enhances proliferation of pancreatic tumor cells. Detected in thymus but not detected in normal colon, but highly expressed in colon cancer biopsies a

Vimentin [EP21]

Anti-vimentin is of limited value as a diagnostic tool; however, when used in combination with other antibodies (in panels) it is useful for the subclassification of a given tumor. Expression of vimentin, when used in conjunction with anti-keratin, is helpful when distinguishing melanomas from undifferentiated carcinomas and large cell lymphomas. All melanomas and Schwannomas react strongly with anti-vimentin. This antibody recognizes a 57 kD intermediate filament. It labels a variety of mesenchymal cells, including melanocytes, lymphocytes, endothelial cells, and fibroblasts. Non-reactivity of anti-vimentin is often considered more useful than its positive reactivity, since there are a few tumors that do not contain vimentin, e.g. hepatoma and seminoma. Anti-vimentin is also useful as a tissue process control reagent.

Vimentin [EP21]